Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Arrayit Corp ARYC

Arrayit Corporation provides microarray tools to life sciences researchers worldwide for discoveries in biomedicine and agriculture. New clinical tests, safer medicines, better crop plants and breathtaking insights into human disease are among the many possibilities afforded by the Company’s microarray technology. The Company’s products and services include Cleanroom, Microarry Buffers... see more

GREY:ARYC - Post Discussion

Arrayit Corp > Endorsed by Peanut Tillman you say?
View:
Post by JuiceNewton on Oct 19, 2018 8:34pm

Endorsed by Peanut Tillman you say?

Is he gonna ball punch this one up to $.3?
Comment by bobzuruncle on Oct 31, 2018 8:27pm
This post has been removed in accordance with Community Policy
Comment by bobzuruncle on Oct 31, 2018 8:36pm
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities